Sign In
Buy OCGN
$1.22
+0.0100 (+0.83%)
At Close: Jun 15, 2026
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
05:35pm, Sunday, 05'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Comp
NEW YORK , May 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, bo
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
09:45am, Friday, 03'rd May 2024
NEW YORK , May 3, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) a
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
07:15am, Thursday, 02'nd May 2024
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
06:30am, Friday, 26'th Apr 2024
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
05:05pm, Friday, 19'th Apr 2024
Ocugen, Inc. expects preliminary safety/efficacy data from phase 1/2 study, using OCU-410 for the treatment of patients with GA, in 2024. Preliminary safety/efficacy data from phase 1/2 study, using O
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
01:17pm, Monday, 08'th Apr 2024
Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.
Why Is Ocugen (OCGN) Stock Up 7% Today?
10:57am, Monday, 08'th Apr 2024
Ocugen (NASDAQ: OCGN ) stock rose about 10% over the weekend. This comes after the company won U.S. Food and Drug Administration (FDA) clearance to advance its rare eye disease treatment to a Phase 3
Ocugen stock price is flying: beware of this crucial OCGN risk
04:06am, Sunday, 07'th Apr 2024
Ocugen (NASDAQ: OCGN) stock price has been one of the best-performing companies in Wall Street this year. It has jumped by more than 218% in 2024, beating some of the best-known brands like Nvidia and
OCGN Stock Alert: Why Is Ocugen Up 20% Today?
03:30pm, Friday, 05'th Apr 2024
Biotechnology firm Ocugen (NASDAQ: OCGN ) — which specializes in developing gene therapies to address blindness diseases — saw its shares move higher on an encouraging clinical development. An adv
OCGN Stock Falls Ocugen Must Restate Its Financials
03:15pm, Tuesday, 02'nd Apr 2024
Shares of once high-flying biotech company Ocugen (NASDAQ: OCGN ) are seeing some selling pressure again today. At the time of writing, OCGN stock is down over 9% on a business update provided by the
MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel
Why Is Ocugen (OCGN) Stock Up 20% Today?
11:58am, Monday, 25'th Mar 2024
Ocugen (NASDAQ: OCGN ) stock is up on Monday as investors celebrate an update on class action lawsuit that the clinical-stage biopharmaceutical company was facing. This lawsuit came from investors wh
